# Tinostamustine Conditioning and Autologous Stem Cell

> **NCT03687125** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mundipharma-EDO GmbH** · enrollment: 6 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma Progression
- Multiple Myeloma With Failed Remission

## Interventions

- **DRUG:** Tinostamustine
- **PROCEDURE:** Autologous Stem Cell Transplant (ASCT)

## Key facts

- **NCT ID:** NCT03687125
- **Lead sponsor:** Mundipharma-EDO GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-15
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-17
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision based on adverse events limiting administration of higher doses required to achieve myeoblative conditioning necessary in this population
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03687125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03687125, "Tinostamustine Conditioning and Autologous Stem Cell". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03687125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*